SRC and neoplasm: The use of the human colon cancer DLD-1 cell line bearing a heterozygous mutation of KRAS, as well as isogenic derivatives with wild-type or homozygous KRAS mutation, revealed the enrichment of this oncoprotein in exosomes concurrently with other tumor-promoting proteins, including EGFR and SRC family kinases [29].